Summary
Biocon & Amylin Pharma tie up is step in the right direction for Biocon.
Currently due to restrictive international laws Bio similars are not easy to market in EU & US markets.
The only way to get around this is to come up with your own Innovative products.
This is what Biocon & Amylin have set out to achieve.
Analysis
Biocon with is cost effective development centers & Amylin with is research leads are trying to come together for a cost effective development program.
In future this is going to the strategy for most pharma companies.
Drug Pipe line of pharma companies are drying up, one of the reasons is Cost!!!
The only way to keep the pipeline buzzing is cost management.
Indian & other low cost centers are bound to again in the near term.
Biocon, Shanta Biotech (now part of Sanofi) Dr. Reddy's and other emerging biotech companies are trying their level best to present them selfeves to this emerging market segment.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
